首页> 外文期刊>Hypertension: An Official Journal of the American Heart Association >Angiotensin I–Converting Enzyme Antisense Gene Therapy Causes Permanent Antihypertensive Effects in the SHR
【24h】

Angiotensin I–Converting Enzyme Antisense Gene Therapy Causes Permanent Antihypertensive Effects in the SHR

机译:血管紧张素I转换酶反义基因治疗在SHR中引起永久性降压作用

获取原文
       

摘要

Abstract —The renin-angiotensin system plays a critical role in the control of blood pressure (BP), and its hyperactivity is associated with the development and maintenance of hypertension. Although traditional pharmacological therapies targeted toward the inhibition of the renin-angiotensin system are effective in the control of this disease, they pose significant limitations. We used an antisense gene delivery strategy to circumvent these limitations and established that a single intracardiac administration of angiotensin type 1 receptor antisense (AT1R-AS) causes permanent prevention of hypertension in the spontaneously hypertensive rat (SHR), an animal model of primary human hypertension. Our objectives in this study were 2-fold: to determine (1) whether the targeting of angiotensin I–converting enzyme (ACE) mRNA by a similar antisense strategy would prevent the SHR from developing hypertension and (2) whether the antihypertensive phenotype is transmitted to the offspring from the antisense-treated parents. Administration of a retroviral vector containing ACE antisense (LNSV-ACE-AS) caused a modest yet significant attenuation of high BP (≈15±2 mm Hg) exclusively in the SHR. This was associated with a complete prevention of cardiac and renovascular pathophysiological alterations that are characteristic of hypertension. Like their parents, the F1 generation offspring of the LNSV-ACE-AS–treated SHR expressed lower BP, decreased cardiac hypertrophy, and normalization of renal arterial excitation-coupling compared with offspring derived from the LNSV-ACE-tS (truncated sense)–treated SHR. In addition, the endothelial dysfunction commonly observed in the SHR renal arterioles was significantly prevented in both parents and offspring of the LNSV-ACE-AS–treated SHR. Polymerase chain reaction followed by Southern analysis revealed that the ACE-AS was integrated into the SHR genome and transmitted to the offspring. These observations suggest that transmission of ACE-AS by retroviral vector may be responsible for the transference of normotensive phenotypes in the SHR offspring.
机译:摘要—肾素-血管紧张素系统在控制血压(BP)中起着关键作用,其过度活跃与高血压的发生和维持有关。尽管针对抑制肾素-血管紧张素系统的传统药物治疗在控制该疾病方面是有效的,但它们构成了明显的局限性。我们使用反义基因传递策略来规避这些局限性,并确定一次心内注射血管紧张素1型受体反义(AT1R-AS)可以永久预防自发性高血压大鼠(SHR)的高血压,这是原发性人类高血压的动物模型。我们在这项研究中的目标是2倍:确定(1)通过类似的反义策略靶向血管紧张素I转换酶(ACE)mRNA是否会阻止SHR患高血压,以及(2)是否传递抗高血压表型来自反义父母的后代。含有ACE反义(LNSV-ACE-AS)的逆转录病毒载体的使用仅在SHR中导致高BP(≈15±2 mm Hg)的适度但显着衰减。这与完全预防高血压特有的心脏和肾血管病理生理改变有关。与他们的父母一样,与LNSV-ACE-tS(截短的)衍生的后代相比,LNSV-ACE-AS治疗的SHR的F1代后代表现出较低的BP,降低的心脏肥大和肾动脉兴奋性耦合正常化。治疗过的SHR。此外,在LNSV-ACE-AS治疗的SHR的父母和后代中,SHR肾小动脉中普遍观察到的内皮功能障碍得到了显着预防。聚合酶链反应和随后的Southern分析表明,ACE-AS已整合到SHR基因组中并传播给后代。这些观察结果表明逆转录病毒载体对ACE-AS的传播可能是SHR后代中血压正常表型转移的原因。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号